State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 101–200 of 1,003
Schrag, S. J., Peña, C., Fernández, J., Sánchez, J., Gómez, V., Pérez, E., Feris, J. M., & Besser, R. E. (2001) · JAMA · doi:10.1001/jama.286.1.49 · Cited by 233
Livermore, D. M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.012 · Cited by 232
“The definition of breakpoints, by BSAC and then EUCAST, has become increasingly predicated on pharmacodynamics, a science that has done much to define the critical target parameters predicting success with different antibiotic classes [74,75].”
BackgroundSeyler, L., Cotton, F., Taccone, F. S., De Backer, D., Macours, P., Vincent, J.-L., & Jacobs, F. (2011) · Critical Care · doi:10.1186/cc10257 · Cited by 232
“To be effective, the doses given should reach therapeutic concentrations in the blood and at the site of infection [8-10].”
BackgroundAndes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231
“Several studies with antibacterial drugs have demonstrated that the pharmacokinetic (PK)-pharmacodynamic (PD) parameter predictive of in vivo efficacy is similar for drugs within the same class (4, 24).”
BackgroundBetrosian, A. P., Frantzeskaki, F., Xanthaki, A., & Douzinas, E. E. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.04.002 · Cited by 230
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
“Experimental antifungal pharmacodynamic investigations have been important for the design of optimal dosing strategies and the development of susceptibility breakpoints (1, 2, 5, 17).”
BackgroundMycobacterium avium in the Postgenomic Era
Turenne, C. Y., Wallace, R., & Behr, M. A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-06 · Cited by 226
Pharmacokinetic and Pharmacodynamic Properties of Meropenem
Nicolau, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590064 · Cited by 226
“regimens [1, 2].”
A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*
Roberts, J. A., Webb, S., Paterson, D., Ho, K. M., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0054d · Cited by 225
“Hanes et al (47) USA; Glaxo Wellcome Critically ill trauma Ceftazidime Not clear No No Nil stated 14 (11) 17 (13)”
BackgroundInfluentialVancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
Dagan, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.2.129 · Cited by 223
“pneumoniae.(16,40,41) This is equivalent to a mean antibiotic”
BackgroundSelf-citationTreatment of Helicobacter pylori infection: Current status and future concepts
Yang, J.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5283 · Cited by 222
Respiratory Syncytial Virus Infection in Elderly Adults
Falsey, A. R., & Walsh, E. E. (2005) · Drugs & Aging · doi:10.2165/00002512-200522070-00004 · Cited by 220
Risk factors and treatment outcomes in osteomyelitis
Tice, A. D. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg186 · Cited by 220
Campbell, S. G., Marrie, T. J., Anstey, R., Dickinson, G., & Ackroyd-Stolarz, S. (2003) · Chest · doi:10.1378/chest.123.4.1142 · Cited by 219
Crump, J. A., Barrett, T. J., Nelson, J. T., & Angulo, F. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375602 · Cited by 216
“Ratios of serum peak antimicrobial concentration to MIC (peak/MIC) and ratios of 24-h area under the serum concentration-versus-time curve (AUC) to MIC are the major PK/PD determinants of activity for fluoroquinolones [64, 65].”
BackgroundHo, P. L., Tse, W. S., Tsang, K. W. T., Kwok, T. K., Ng, T. K., Cheng, V. C. C., & Chan, R. M. T. (2001) · Clinical Infectious Diseases · doi:10.1086/319222 · Cited by 216
“a therapeutic index (ratio of drug level at site of infection to MIC) of 10-16 has been suggested to be required for prevention of the emergence of resistant mutants during treatment with fluoroquinolones [32-34].”
BackgroundPhenotypic Tolerance: Antibiotic Enrichment of Noninherited Resistance in Bacterial Populations
Wiuff, C., Zappala, R. M., Regoes, R. R., Garner, K. N., Baquero, F., & Levin, B. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1483-1494.2005 · Cited by 215
Martinez, M. N., Papich, M. G., & Drusano, G. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05360-11 · Cited by 215
“Craig and Dalhoff (14) concluded that for drugs that exhibit concentration-dependent killing properties, such as fluoroquinolones, the Cmax/MIC ratio may be particularly important for a pathogen with a high MIC or one that is proliferating rapidly.”
Methodde With, K., Allerberger, F., Amann, S., Apfalter, P., Brodt, H.-R., Eckmanns, T., Fellhauer, M., Geiss, H. K., Janata, O., Krause, R., et al. (2016) · Infection · doi:10.1007/s15010-016-0885-z · Cited by 215
“Betalactams with short half lives (<2 h) should actually be given as extended or continuous infusion, which requires drug stability at room temperature [317, 318].”
Clinical Pharmacokinetics of Clarithromycin
Rodvold, K. A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937050-00003 · Cited by 214
Carbapenems: a potent class of antibiotics
Nicolau, D. P. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.1.23 · Cited by 213
“In contrast to the efficacy of aminoglycosides and fluoroquinolones, which is concentration-dependent, the efficacy of carbapenems and other β -lactams is time-dependent (i.e., directly related to the percentage of the dosing interval during which free-drug concentration exceeds minimum inhibitory concentration [%T >…”
BackgroundAnalysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection
McWhinney, B. C., Wallis, S. C., Hillister, T., Roberts, J. A., Lipman, J., & Ungerer, J. P. J. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.05.027 · Cited by 209
Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy
Tice, A. D., Hoaglund, P. A., & Shoultz, D. A. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00231-6 · Cited by 209
Therapeutic Potential of Plants as Anti‐Microbials for Drug Discovery
Perumal Samy, R., & Gopalakrishnakone, P. (2010) · Evidence-Based Complementary and Alternative Medicine · doi:10.1093/ecam/nen036 · Cited by 207
Bacterial Meningitis in Children
Chávez-Bueno, S., & McCracken, G. H. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.02.011 · Cited by 204
“Their effectiveness is determined by the ratio between the peak concentration or area under the concentration curve of the antibiotic and the MBC of the pathogen [52].”
BackgroundShandil, R. K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharath, S., & Balasubramanian, V. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00414-06 · Cited by 203
“These agents do not exhibit concentration-dependent killing in vitro, but fAUC/MIC best correlates with their in vivo efficacy, and this in turn has been linked to their lengthy in vivo postantibiotic effects (5).”
BackgroundZuluaga, A. F., Salazar, B. E., Rodriguez, C. A., Zapata, A. X., Agudelo, M., & Vesga, O. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-55 · Cited by 202
“It allowed the quantitative determination of pharmacokinetic (PK) and pharmacodynamic (PD) indices (PK/PD) useful to predict antibiotic efficacy while minimizing selection of resistant mutants [2].”
BackgroundYang, J.-C., Lin, C.-J., Wang, H.-L., Chen, J.-D., Kao, J. Y., Shun, C.-T., Lu, C.-W., Lin, B.-R., Shieh, M.-J., Chang, M.-C., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.036 · Cited by 202
Mouton, J. W., Ambrose, P. G., Canton, R., Drusano, G. L., Harbarth, S., MacGowan, A., Theuretzbacher, U., & Turnidge, J. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.005 · Cited by 200
Clinical Practice Guideline on Adult Sinusitis
Rosenfeld, R. M. (2007) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2007.07.021 · Cited by 200
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem
Kuti, J. L., Dandekar, P. K., Nightingale, C. H., & Nicolau, D. P. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003257225 · Cited by 199
White, A. R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh050 · Cited by 198
Fosfomycin: Pharmacological, Clinical and Future Perspectives
Dijkmans, A. C., Zacarías, N. V. O., Burggraaf, J., Mouton, J. W., Wilms, E., Van Nieuwkoop, C., Touw, D. J., Stevens, J., & Kamerling, I. M. C. (2017) · Antibiotics · doi:10.3390/antibiotics6040024 · Cited by 198
“Because the exposure-response relationship can differ between antibiotics, it is important to define the correct PK/PD index for each antibiotic in order to establish the PK/PD target value that will maximize clinical efficacy [11,81,82].”
BackgroundThe use of antimicrobial agents in broiler chickens
Landoni, M. F., & Albarellos, G. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.016 · Cited by 196
Pharmacokinetics and Pharmacodynamics of Antimicrobials
Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/518137 · Cited by 194
“For penicillins, these end points occur at 30% and 50% of the dosing interval [7].”
BackgroundPiperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Gin, A. S., Dilay, L., Karlowsky, J. A., Walkty, A. J., Rubinstein, E., & Zhanel, G. G. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.365 · Cited by 194
Do we still need the aminoglycosides?
Durante-Mangoni, E., Grammatikos, A., Utili, R., & Falagas, M. E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.09.001 · Cited by 193
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
“Thus, continuous infusion or frequent dosing maximizes the time-dependent parameter that predicts efficacy or the time that levels in serum remain above the MIC for the infecting organisms (9, 29).”
BackgroundMethodResultInfluentialDelivery of Gentamicin to the Rabbit Eye by Drug-Loaded Hydrogel Iontophoresis
Eljarrat-Binstock, E., Raiskup, F., Stepensky, D., Domb, A. J., & Frucht-Pery, J. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1294 · Cited by 192
Kasiakou, S. K., Sermaides, G. J., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70218-8 · Cited by 189
Antimicrobial resistance in livestock
Catry, B., Laevens, H., Devriese, L. A., OPSOMER, G., & de Kruif, A. (2003) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.2003.00463.x · Cited by 189
Abdul-Aziz, M., Lipman, J., Mouton, J., Hope, W., & Roberts, J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398490 · Cited by 188
“30 The fi rst category includes antibiotics where the difference between the maximum effect and minimum effect is relatively large, and increasing concentrations result in progressively increased killing.”
Bush, K. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.08.011 · Cited by 188
“Although the efficacy of imipenem is related to the time the drug concentration exceeds a defined threshold [128], efficacy of the combination with relebactam (and cilastatin) is less well established.”
BackgroundRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Dalley, A. J., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.008 · Cited by 188
The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline
Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J. (2005) · Clinical Infectious Diseases · doi:10.1086/431674 · Cited by 188
“For antimicrobial agents with moderate to prolonged postantibiotic effects, however, the time of exposure is less important, and the ratio of AUC to MIC is the important determinant of efficacy [27].”
Hazir, T., Fox, L. M., Nisar, Y. B., Fox, M. P., Ashraf, Y. P., MacLeod, W. B., Ramzan, A., Maqbool, S., Masood, T., Hussain, W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60071-9 · Cited by 186
Ertapenem, the first of a new group of carbapenems
SHAH, P. M., & Isaacs, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg404 · Cited by 186
Hengzhuang, W., Wu, H., Ciofu, O., Song, Z., & Høiby, N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06486-11 · Cited by 185
“Knowledge of both the kinetics of antimicrobial activity and the kinetics of drug concentrations in serum and tissues allows us to establish dosage regimens for most drugs that might be used for therapy (13, 14).”
BackgroundPharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia
Ariano, R. E., Nyhlén, A., Donnelly, J. P., Sitar, D. S., Harding, G. K., & Zelenitsky, S. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e271 · Cited by 185
Felmingham, D., Washington, J., & Group, T. A. P. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.supplement-2.5 · Cited by 185
Sime, F. B., Roberts, M. S., Peake, S. L., Lipman, J., & Roberts, J. A. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-35 · Cited by 184
“Animal studies suggest that maximal effects can be achieved when f T>MIC is less than 100% of the dosing interval, depending on the antibiotic and the organism targeted [51,53,105].”
BackgroundHuttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv201 · Cited by 184
Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., Drusano, G. L., & Hoover, J. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02307-18 · Cited by 181
“Recommendations (Table 2) have been developed based on experiments that predicted clinical success (1, 2, 100), and this topic has been reviewed previously (101).”
BackgroundMethodInfluentialProperties and potential of ertapenem
Livermore, D. M., Sefton, A. M., & Scott, G. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg375 · Cited by 181
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180
“The time course of antimicrobial activity can be determined by two characteristics: the effect of increasing drug concentrations on the extent of organism killing and the presence or absence of antimicrobial effects which persist after serum levels have fallen below the MIC (9).”
BackgroundResultInfluentialAbdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., De Waele, J. J., Devaux, A., Di Tanna, G. L., Dulhunty, J. M., Elkady, H., Eriksson, L., et al. (2024) · JAMA · doi:10.1001/jama.2024.9803 · Cited by 180
Foerster, S., Unemo, M., Hathaway, L. J., Low, N. N., & Althaus, C. L. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0838-9 · Cited by 179
Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics
Yu, G., Baeder, D. Y., Regoes, R. R., & Rolff, J. (2018) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2017.2687 · Cited by 178
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
“Studies with numerous antimicrobials have also shown that the magnitude of the PK-PD parameter required for efficacy is similar for drugs within the same class, provided free drug concentrations are considered, and it is similar in the treatment of organisms with reduced susceptibility (3, 5).”
BackgroundOptimising drug dosing in patients receiving extracorporeal membrane oxygenation
Cheng, V., Abdul-Aziz, M.-H., Roberts, J. A., & Shekar, K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.154 · Cited by 177
“The beta-lactam’s optimal bactericidal killing is achieved when the free (unbound) drug concentration remains four-to-five times above the minimum inhibitory concentration (MIC) of a pathogen for extended periods during a dosing interval (fT>MIC) (54,55).”
BackgroundMouton, J. W., & Vinks, A. A. T. M. M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00005 · Cited by 177
Single-Dose Azithromycin for the Treatment of Cholera in Adults
Saha, D., Karim, M. M., Khan, W. A., Ahmed, S., Salam, M. A., & Bennish, M. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054493 · Cited by 175
Bunker, A., & Róg, T. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.604770 · Cited by 174
“…the interactions of drugs and drug metabolites, as their distribution varies in time in the different tissues of the organism; this form of numerical computational modeling is known as pharmacokinetic/pharmacodynamics modeling (Craig, 1998; Ruiz-Garcia et al., 2008; Belfo and Lemos, 2021).”
BackgroundThe millennium bugs — the need for and development of new antibacterials
Bax, R. P., Mullan, N. A., & Verhoef, J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00189-8 · Cited by 174
Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
González, D., Schmidt, S., & Derendorf, H. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00092-12 · Cited by 173
“serum divided by the MIC (Cmax/MIC) and AUC/MIC ratio that are important (155, 156).”
BackgroundAntibiotic Use in the Intensive Care Unit: Optimization and De-Escalation
Campion, M., & Scully, G. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618762747 · Cited by 172
Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps
Yılmaz, Ç., & Özcengiz, G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.005 · Cited by 172
“[27] who revealed time-dependent, concentration-dependent and mixed patterns of these for different antibiotics including penicillin and streptomycin and re-emerged by the effort of Craig (1998) [27,28].”
BackgroundDulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.9779 · Cited by 171
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients
Li, C., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291035 · Cited by 171
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
Onufrak, N. J., Forrest, A., & Gonzalez, D. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.015 · Cited by 170
Roberts, J. A., Joynt, G. M., Lee, A., Choi, G., Bellomo, R., Kanji, S., Mudaliar, M. Y., Peake, S. L., Stephens, D., Taccone, F. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa224 · Cited by 151
Toutain, P.-L., Bousquet-Mélou, A., Damborg, P., Ferran, A. A., Mevius, D., Pelligand, L., Veldman, K. T., & Lees, P. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02344 · Cited by 169
“for Gram-negative pathogens is associated with a high likelihood of success both clinically in humans and in rodent models (Craig, 1998).”
BackgroundIn Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis
Andes, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1179-1186.2003 · Cited by 169
“These studies have demonstrated that the magnitude of a pharmacodynamic parameter associated with efficacy is similar for drugs within the same class, provided that free drug levels are considered (9, 11, 19).”
BackgroundMethodInfluentialGotfried, M. H., Danziger, L. H., & Rodvold, K. A. (2001) · CHEST Journal · doi:10.1378/chest.119.4.1114 · Cited by 169
Zhanel, G. G., Sniezek, G., Schweizer, F., Zelenitsky, S. A., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2009) · Drugs · doi:10.2165/00003495-200969070-00003 · Cited by 168
Papich, M. G. (2014) · Veterinary Microbiology · doi:10.1016/j.vetmic.2013.12.021 · Cited by 167
Nagai, K., Davies, T. A., Jacobs, M. R., & Appelbaum, P. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1273-1280.2002 · Cited by 167
“We should not forget that these relationships are not the only determinants of the clinical relevance of these agents, which is also determined by the pharmacokinetic parameters achieved with the dosing regimen chosen and the pharmacodynamic properties of the agent (9).”
BackgroundPea, F., & Furlanut, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00004 · Cited by 165
“[392,393] On the other hand, β-lactam agents and glycopeptides exhibit time-dependent bactericidal activity, and time above MIC is considered the major determinant of their efficacy.[394-396] Therefore, as a general rule, the strategy for choosing the dosage regimen should differ according to the kind of antibacterial…”
Pulmonary infections complicating ARDS
Luyt, C.-E., Bouadma, L., Morris, A. C., Dhanani, J. A., Kollef, M., Lipman, J., Martin-Loeches, I., Nseir, S., Ranzani, O. T., Roquilly, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06292-z · Cited by 164
Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives.
Bambeke, F. V., Barcia-Macay, M., Lemaire, S., & Tulkens, P. M. (2006) · PubMed · Cited by 163
Optimal Drug Synergy in Antimicrobial Treatments
Torella, J. P., Chait, R., & Kishony, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000796 · Cited by 162
“aeruginosa infection model [22–24] and provided a mathematical model that quantitatively described”
BackgroundTängdén, T., Martin, V., Felton, T., Nielsen, E. I., Marchand, S., Brüggemann, R. J. M., Bulitta, J. B., Bassetti, M., Theuretzbacher, U., Tsuji, B. T., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4780-6 · Cited by 162
The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis
Reed, M. D., Stern, R. C., O’Riordan, M. A., & Blumer, J. L. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010537 · Cited by 162
“For example, if 90% of sputum colistin is bound, a local, total colistin concentration of at least 200 mg/L would be necessary to exceed the minimum inhibitory concentration (MIC) for important sputum isolates (MIC < 2 mg/L)(7) by at least 10-fold to potentially predict clinical efficacy using similar pharmacodynamic…”
BackgroundSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
CUESTA, N. R., Martín‐Suárez, A., Pérez, M. P., Martín-González, F., & Gatta, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03679.x · Cited by 161
Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections
Bauer, K. A. A., West, J. E., O’Brien, J. M., & Goff, D. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02365-12 · Cited by 161
Feikin, D. R., & Klugman, K. P. (2002) · Clinical Infectious Diseases · doi:10.1086/341896 · Cited by 160
“Moreover, the doses of antibiotics given for invasive infections are usually high enough to kill pneumococci with mildly elevated penicillin MICs, which was the level of resistance that first occurred [41, 50].”
BackgroundNelson, C. L., McLaren, S. G., Skinner, R. A., Smeltzer, M. S., Thomas, J. R., & Olsen, K. M. (2002) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(01)00133-4 · Cited by 160
Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis
Wong, S. Y., Lee, J. S., Kwak, H.-K., Via, L. E., Boshoff, H. I., & Barry, C. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01814-10 · Cited by 161
“For aminoglycosides, which exhibit concentration-dependent killing, Cmax/MIC is the pharmacodynamic parameter that best correlates with bactericidal activity and clinical response (8, 21, 25).”
BackgroundBiogenic ammonia modifies antibiotic resistance at a distance in physically separated bacteria
Bernier, S. P., Létoffé, S., Delepierre, M., & Ghigo, J. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07724.x · Cited by 159
“Exposure to biogenic ammonia has potential clinical implications, since increase in MIC in ammonia-rich bacterial infection sites can affect pharmacokinetic and pharmacodynamic parameters during antibiotherapy using aminopenicillin or tetracycline (Craig, 1998).”
BackgroundSakka, S. G., Glauner, A. K., Bulitta, J. B., Kinzig-Schippers, M., Pfister, W., Drusano, G. L., & Sörgel, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01318-06 · Cited by 159
“Previous studies (3, 7, 17, 28) repeatedly emphasized that the time that the antibiotic concentration exceeds the MIC best predicts the microbiological and clinical success of -lactams.”
BackgroundResultVarghese, J. M., Roberts, J. A., & Lipman, J. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.09.006 · Cited by 159
Roberts, J. A., Kirkpatrick, C. M. J., & Lipman, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq449 · Cited by 158
Udy, A. A., Lipman, J., Jarrett, P., Klein, K., Wallis, S. C., Patel, K., Kirkpatrick, C. M., Kruger, P. S., Paterson, D. L., Roberts, M. S., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0750-y · Cited by 138
“For β-lactams, preclinical studies support maintaining prolonged free drug concentrations above the minimum inhibitory concentration (MIC) of the likely pathogen [6].”
BackgroundMontero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., Tubau, F., Borraz, C., & Gudiol, F. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh485 · Cited by 158
“baumannii.(27,41) To our knowledge, no clinical data are currently available to evaluate the systematic use of the b-lactam– aminoglycoside combination to treat serious A.”
BackgroundAntimicrobial Treatment Guidelines for Acute Bacterial Rhinosinusitis
(2000) · Otolaryngology · doi:10.1067/mhn.2000.107873 · Cited by 158
“68, 69 The relationship between the T > MIC and clinical efficacy has been evaluated in patients with acute otitis media caused by S pneumoniae and H influenzae.”
Backgroundde Velde, F., Mouton, J. W., de Winter, B. C. M., van Gelder, T., & Koch, B. C. P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.005 · Cited by 156
Ankomah, P., & Levin, B. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400352111 · Cited by 157
“One answer has been to combine in vitro studies of the pharmacodynamics (PD) of the antibiotics and bacteria and the in vivo pharmacokinetics (PK) of the antibiotics in treated patients or model organisms (1, 2).”
BackgroundPharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models
Andes, D., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1665-1670.2002 · Cited by 137
Self-citation
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.